Glaxo Reaches $2.2 Billion Dementia Drug Deal With Alector – Yahoo Finance

(Bloomberg) — GlaxoSmithKline Plc agreed to pay U.S. biotech Alector Inc. as much as $2.2 billion to develop therapies targeting diseases such as Parkinsons and Alzheimers, the latest step by the U.… [+2859 chars]